1. Home
  2. OUST vs PHVS Comparison

OUST vs PHVS Comparison

Compare OUST & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ouster Inc.

OUST

Ouster Inc.

HOLD

Current Price

$34.32

Market Cap

2.9B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$35.00

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OUST
PHVS
Founded
2015
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
OUST
PHVS
Price
$34.32
$35.00
Analyst Decision
Strong Buy
Buy
Analyst Count
4
11
Target Price
$39.25
$41.82
AVG Volume (30 Days)
2.6M
617.7K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
48.56
N/A
EPS
N/A
N/A
Revenue
$169,384,000.00
N/A
Revenue This Year
$33.20
N/A
Revenue Next Year
$37.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
52.46
N/A
52 Week Low
$16.40
$20.65
52 Week High
$63.79
$38.13

Technical Indicators

Market Signals
Indicator
OUST
PHVS
Relative Strength Index (RSI) 38.81 47.99
Support Level $31.95 $24.73
Resistance Level $50.62 $36.80
Average True Range (ATR) 2.91 1.80
MACD -0.98 -0.10
Stochastic Oscillator 2.70 36.35

Price Performance

Historical Comparison
OUST
PHVS

About OUST Ouster Inc.

Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and the Pacific, Europe, the Middle East, and Africa. It derives maximum revenue from the Americas. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensor kits.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: